The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,
Melanoma News
RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy
RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.
Novel Combo Shows Early Activity in PD-L1–Resistant NSCLC, Melanoma
Glycan editing of cell surface glycans with E-602 may represent a novel therapeutic approach among patients with cancer.
Retrospective Analysis Across Six CheckMate Trials Reinforces Benefit of Nivolumab Plus Ipilimumab
A pooled analysis of six CheckMate studies in immune checkpoint inhibitor (ICI), specifically treatment with nivolumab plus ipilimumab (NIVO + IPI) versus NIVO monotherapy, aimed to describe the long-term overall survival in patients with ICI treatment-naïve unresectable/metastatic melanoma.